Back to Search
Start Over
H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy.
- Source :
-
Cells [Cells] 2019 May 22; Vol. 8 (5). Date of Electronic Publication: 2019 May 22. - Publication Year :
- 2019
-
Abstract
- Acetylation and deacetylation are posttranslational modifications (PTMs) which affect the regulation of chromatin structure and its remodeling. Acetylation of histone 3 at lysine placed on position 18 (H3K18Ac) plays an important role in driving progression of many types of cancer, including breast, colon, lung, hepatocellular, pancreatic, prostate, and thyroid cancer. The aim of this review is to analyze and discuss the newest findings regarding the role of H3K18Ac and acetylation of other histones in carcinogenesis. We summarize the level of H3K18Ac in different cancer cell lines and analyze its association with patients' outcomes, including overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS). Finally, we describe future perspectives of cancer therapeutic strategies based on H3K18 modifications.
- Subjects :
- Acetylation drug effects
Animals
Antineoplastic Agents therapeutic use
Biomarkers, Tumor antagonists & inhibitors
Cell Line, Tumor
Disease Progression
Disease-Free Survival
Histones antagonists & inhibitors
Humans
Male
Mice
Progression-Free Survival
Protein Processing, Post-Translational
Antineoplastic Agents pharmacology
Biomarkers, Tumor metabolism
Histones metabolism
Neoplasms drug therapy
Neoplasms metabolism
Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 2073-4409
- Volume :
- 8
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Cells
- Publication Type :
- Academic Journal
- Accession number :
- 31121824
- Full Text :
- https://doi.org/10.3390/cells8050485